Global Information Lookup Global Information

Maftivimab information


Maftivimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetZaire ebolavirus glycoprotein
Clinical data
Pronunciationmaf tiv' i mab
License data
  • US DailyMed: Maftivimab
Drug classMonoclonal antibody
ATC code
  • None
Identifiers
CAS Number
  • 2135632-36-7
UNII
  • KOP95331M4
KEGG
  • D11450
Chemical and physical data
FormulaC6368H9886N1706O2008S46
Molar mass143947.83 g·mol−1

Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).[1][2]

  1. ^ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

and 13 Related for: Maftivimab information

Request time (Page generated in 0.5655 seconds.)

Maftivimab

Last Update:

Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab...

Word Count : 126

Ebola

Last Update:

approved treatment for Ebola as of 2019[update], two treatments (atoltivimab/maftivimab/odesivimab and ansuvimab) are associated with improved outcomes. Supportive...

Word Count : 18113

ZMapp

Last Update:

atoltivimab/maftivimab/odesivimab and ansuvimab. In October 2020, the U.S. Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab...

Word Count : 2654

WHO Model List of Essential Medicines

Last Update:

Benznidazole Nifurtimox Ivermectin Ansuvimab Atoltivimab/maftivimab/odesivimab (atoltivimab + maftivimab + odesivimab) No listings in this section. Acetylsalicylic...

Word Count : 4835

Regeneron Pharmaceuticals

Last Update:

Libtayo was approved by the FDA in September 2018. Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of three antibodies, developed to treat deadly...

Word Count : 2239

Atoltivimab

Last Update:

monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus)...

Word Count : 167

Ebola virus disease treatment research

Last Update:

in nature. As of August 2023[update], treatment known as atoltivimab/maftivimab/odesivimab and experimental ansuvimab were found to be 90% effective....

Word Count : 3518

Odesivimab

Last Update:

monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus)...

Word Count : 126

Remdesivir

Last Update:

than monoclonal antibody treatments such as ansuvimab and atoltivimab/maftivimab/odesivimab. The trials, however, established its safety profile. Remdesivir...

Word Count : 9806

Kivu Ebola epidemic

Last Update:

several drugs used to treat EVD, including Remdesivir, ZMapp, atoltivimab/maftivimab/odesivimab, ansuvimab and favipiravir. The drug ansuvimab (which is a...

Word Count : 18708

Ansuvimab

Last Update:

Institutes of Health promoted the use of ansuvimab, alongside atoltivimab/maftivimab/odesivimab, a similar Regeneron-produced monoclonal antibody treatment...

Word Count : 2354

List of drugs granted breakthrough therapy designation

Last Update:

Pitolisant Harmony Biosciences cataplexy in adults with narcolepsy Atoltivimab/maftivimab/odesivimab-ebgn Regeneron Ebola Zaire Lonafarnib Eiger BioPharmaceuticals...

Word Count : 180

Galidesivir

Last Update:

antiviral effects of galidesivir in patients with COVID-19. Atoltivimab/maftivimab/odesivimab Bemnifosbuvir Brincidofovir Coronavir 3-Deazaneplanocin A Favipiravir...

Word Count : 561

PDF Search Engine © AllGlobal.net